Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
An experimental antibody-drug conjugate from Merck has succeeded in another Phase 3 cancer study, potentially helping offset Keytruda’s looming patent cliff.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







